Table 1.
Isolated microorganisms, concomitant antibiotics and outcome
| Total (n=133) | Treatment with |
Nephrotoxicity |
|||||
|---|---|---|---|---|---|---|---|
| Daptomycin (n=62) | Vancomycin (n=71) | p | YES (n=21) | NO (n=112) | p | ||
| CNSa | 43 (32.3) | 18 (29.0) | 25 (35.2) | 0.447 | 9 (42.9) | 34 (30.4) | 0.261 |
| MRSAb | 39 (29.3) | 22 (35.5) | 17 (23.9) | 0.145 | 3 (14.3) | 36 (32.1) | 0.099 |
| MSSAc | 21 (15.8) | 11 (17.7) | 10 (14.1) | 0.564 | 4 (19.0) | 17 (15.2) | 0.744 |
| Enterococcus spp. | 24 (18.0) | 11 (17.7) | 14 (19.7) | 0.591 | 5 (23.8) | 19 (17.0) | 0.536 |
| Other Gram-positive bacteria | 9 (6.8) | 2 (3.2) | 7 (9.9) | 0.178 | 1 (4.8) | 8 (7.1) | 1.000 |
| Gram-negative bacteria | 5 (3.8) | 2 (3.2) | 3 (4.2) | 1.000 | 1 (4.8) | 4 (3.6) | 0.583 |
| Concomitant antibiotics | 70 (53.0) | 31 (58.8) | 39 (54.9) | 0.367 | 8 (38.1) | 62 (55.4) | 0.146 |
| Penicillins | 9 (6.8) | 3 (4.8) | 6 (8.5) | 0.502 | 0 (0.0) | 9 (8.0) | 0.353 |
| Cephalosporins | 15 (11.3) | 3 (4.8) | 12 (16.9) | 0.028 | 2 (9.5) | 13 (11.6) | 1.000 |
| Aztreonam | 2 (1.5) | 2 (3.2) | 0 (0.0) | 0.215 | 0 (0.0) | 2 (1.8) | 1.000 |
| Carbapenem | 22 (16.5) | 11 (17.7) | 11 (15.5) | 0.727 | 1 (4.8) | 21 (18.8) | 0.198 |
| Total β-lactams | 48 (36.1) | 19 (30.6) | 29 (40.8) | 0.221 | 3 (14.3) | 45 (40.2) | 0.043 |
| Aminoglycosides | 13 (9.8) | 5 (8.1) | 8 (11.3) | 0.383 | 4 (19.0) | 9 (8.0) | 0.125 |
| Quinolones | 13 (9.8) | 5 (8.1) | 8 (11.3) | 0.383 | 1 (4.8) | 12 (10.7) | 0.691 |
| Rifampicin | 9 (6.8) | 6 (9.7) | 3 (4.2) | 0.301 | 2 (9.5) | 7 (6.3) | 0.633 |
| Others | 8 (6.0) | 4 (6.5) | 3 (4.2) | 0.705 | 1 (4.8) | 6 (5.4) | 1.000 |
| Clinical cure | 117 (88.0) | 55 (88.7) | 62 (87.3) | 0.806 | 15 (71.4) | 102 (91.1) | 0.011 |
| Eradication + presumed eradication | 109 (82.2) | 52 (83.9) | 57 (80.3) | 0.591 | 15 (71.4) | 94 (83.9) | 0.171 |
a
CNS: Coagulase-negative staphylococci
b
MRSA: Methicillin-resistant Staphylococcus aureus
c
MSSA: Methicillin-susceptible Staphylococcus aureus